I'm very curious how Kevetrin did against Prostate
Post# of 72440
I think if Prostate was qualified to be given orphan designation we would have filed for that also. I bet we see terrific results for Prostate.....
What's amazing to me is in the next 2 years we could have 5+ trials running for Kevetrin and even more amazing 5+ trials running for Brilacidin.
2016 will be a very good year but 2017 will be terrific followed by 2018 which will be buyout!!!!
Leo and Menon have roughly 20,000,000 options that expire in 2019, so they need to get the price up as high as possible.
NO BETTER BIO AROUND!